



AP32556 - 071838.0125

PATENT

IN THE CLAIMS:

Please cancel Claims 47, 48, 61-63, 78 and 81 without prejudice.

Please amend Claims 45, 64, 76, 84 and 87 as follows.

RECEIVED  
JAN 22 2002  
TECH CENTER 1600/2900

45. (Amended) A method for ameliorating the effects of a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin with an effective amount of a nucleic acid molecule selected from the group consisting of 5'-ATCTCTCCGCTTCCTTTC-3' (SEQ ID NO:10); 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue of any one of said nucleic acid molecules wherein said nucleic acid molecule or its chemical analogue is capable of reducing the level of IGF-I receptor in said mammal.

64. (Amended) A method of ameliorating the effects of psoriasis in a mammal, said method comprising contacting proliferating skin with an effective amount of one or more nucleic acid molecules or chemical analogues thereof selected from the group consisting of 5'-ATCTCTCCGCTTCCTTTC-3' (SEQ ID NO:10); 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3'

(SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue of any one of said nucleic acid molecules which is capable of interacting with mRNA transcribed from an IGF-I gene, an IGF-I receptor gene or a gene encoding an IGFBP.

76. (Amended) A composition comprising a nucleic acid molecule selected from the group consisting of 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical analogue of any one of said nucleic acid molecules, wherein said nucleic acid or chemical analogue is capable of reducing the level of IGF-I receptor in a mammal said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

84. (Amended) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17) or chemical analogue thereof.

87. (Amended) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) or chemical analogue thereof.